Declaration of Helsinki: Ethics in Human Medical Research

The Declaration of Helsinki is the most influential code of ethics governing medical research involving human participants, and it has held that position for six decades. Adopted by the World Medical Association (WMA) in 1964, it grew out of the same post-World War II reckoning that produced the Nuremberg Code, but it has been revised multiple times since then to keep pace with changes in science, technology, and global health. The most recent revision came in October 2024, marking the document’s eighth update. Despite having no legal force of its own, the Declaration shapes how ethics committees, journal editors, and regulatory bodies around the world evaluate whether a study involving people was conducted responsibly.

What the Declaration Actually Says

At its core, the Declaration of Helsinki establishes that the purpose of medical research is to generate knowledge that improves health, but that this purpose “can never take precedence over the rights and interests of individual research participants.”¹ That single principle underlies everything else in the document. It means a study cannot justify harming or deceiving a participant simply because the data would be scientifically valuable. The knowledge gained must always be weighed against the risks borne by the people who volunteer for the research.

From this foundation, the Declaration lays out requirements that most people involved in medical research will recognize: studies must be reviewed and approved by independent ethics committees before they begin, participants must give informed consent, researchers must minimize risks, and the privacy of participants must be protected. These sound obvious today, but each one was a hard-won principle added because real abuses made it necessary.

How It Has Changed Over Sixty Years

The original 1964 Declaration was a short document, largely responding to the horrors of Nazi medical experimentation exposed at the Nuremberg trials. It affirmed that voluntary consent is essential and that doctors owe a duty to their patients even when those patients are also research subjects. Since then, the WMA has revised the text in 1975, 1983, 1989, 1996, 2000, 2008, 2013, and most recently in 2024.

Each revision reflected the ethical questions of its era. The 2008 revision, for example, introduced an explicit requirement for clinical trial transparency. It mandated that every clinical trial must be registered in a publicly accessible database before the first participant is enrolled, and that researchers have a duty to make their results publicly available.² This was a direct response to growing evidence that pharmaceutical companies were selectively publishing only favorable trial results, distorting the medical literature.

The 2024 revision, adopted on the document’s 60th anniversary, was developed over more than two years of international consultation. It expanded the Declaration’s scope to cover research involving not just human participants directly, but also human data and human cells and tissues, reflecting the explosion of biobank research and big-data health studies.³ It also tackled questions around global health emergencies and data privacy that earlier versions had not needed to address.

The Placebo Problem

No provision of the Declaration has generated more sustained controversy than the paragraphs governing the use of placebos in clinical trials. The core question sounds simple: when a treatment already exists for a condition, is it ethical to give some study participants a sugar pill instead? The Declaration’s answer has swung back and forth across revisions, and the research community remains genuinely divided.⁴

On one side are those who argue that participants should never be denied a proven treatment. If a drug already works for their condition, randomly assigning them to a placebo arm exposes them to unnecessary suffering. On the other side are researchers and regulators who point out that placebo-controlled trials produce cleaner data and are sometimes the only reliable way to measure whether a new treatment works at all. Both camps have lobbied hard for revisions to the Declaration that support their position.

The current text tries to thread the needle. It permits placebo use in limited circumstances, such as when no proven intervention exists, when there are compelling methodological reasons, or when the patients receiving placebo would not suffer serious or irreversible harm. Researchers working in psychiatry, where symptoms can be severe but existing treatments are imperfect, have proposed specific criteria for judging when placebo arms are acceptable. These include evaluating whether the new treatment is likely to offer real clinical advantages over what already exists, whether participant selection can minimize the chance of serious harm, and whether the overall risk-benefit balance favors inclusion of a placebo group.⁵

This remains one of the most contested areas in research ethics, particularly when trials are conducted in low-income countries where participants may have no access to any treatment outside the study. In those settings, the placebo question is not just methodological but deeply political.

Vulnerability and the Shift Toward Inclusion

For most of its history, the Declaration’s approach to people considered “vulnerable” was straightforward: protect them by limiting their participation in research. Children, prisoners, people with cognitive disabilities, and populations in resource-poor settings were treated as groups needing extra barriers between them and the research enterprise. The logic was understandable given the history of exploitation, but it created a serious unintended consequence. Groups excluded from studies were also excluded from the benefits that research produces. Drugs were approved without data on how they worked in pregnant people, elderly populations, or people living in the very countries where certain diseases were most common.

The 2024 revision marks a significant philosophical shift. Rather than treating vulnerability as a fixed category attached to certain groups, the new language describes “situations of more vulnerability” that can be contextual and dynamic. The revised text explicitly states that the harms of excluding vulnerable populations from research must be weighed against the harms of including them, and that exclusion “can potentially perpetuate or exacerbate their disparities.”⁶ The Declaration now says that research involving people in situations of particular vulnerability is justified when it is responsive to their health needs and priorities, and when they stand to benefit from the results. Researchers should only default to less vulnerable groups when doing so would not perpetuate existing health gaps.

This is a meaningful change in framing. It moves the ethical conversation from “keep vulnerable people out” to “include them responsibly, with appropriate protections.” Some bioethicists have noted that this aligns the Declaration more closely with the approach taken by the Council for International Organizations of Medical Sciences (CIOMS), which had already adopted a more nuanced view of vulnerability.⁷

What Happens After the Trial Ends

A question that receives surprisingly little public attention is what researchers owe participants once a study is over. If a trial demonstrates that a new drug works, and you were in the treatment arm and it helped you, do you get to keep taking it? What if you were in the placebo arm and now want access?

The Declaration addresses this through what ethicists call post-trial obligations, and the 2013 version identified at least two distinct types: access to care after the study ends and access to the information generated by the research. The agents responsible for meeting these obligations include the sponsors who funded the study, the researchers who conducted it, and the governments of host countries.⁸

In practice, this is where ethical principles collide with economic realities. A pharmaceutical company may test a drug in a developing country because the disease is prevalent there and enrollment is faster. When the trial ends, providing continued access to an expensive new medication in a healthcare system that cannot afford it is a genuine logistical and financial challenge. The Declaration states the obligation, but enforcing it is another matter entirely, since the document carries moral authority rather than legal power.

Not a Law, but Something More Flexible

One of the most common misconceptions about the Declaration of Helsinki is that it is a binding legal instrument. It is not. The WMA is a confederation of national medical associations, not a government body, and it has no legal authority to compel anyone to do anything. The Declaration is, as one editorial in JAMA put it, “an ethical document” whose influence comes from “its sound and respected recommendations” rather than from any enforcement mechanism.⁹

That said, its practical reach is enormous. Most medical journals require authors to state that their research was conducted in accordance with the Declaration. Ethics committees and institutional review boards around the world reference it when evaluating study protocols. The principles of the Declaration inform the publication ethics standards for clinical trial reports, shaping requirements around protocol transparency and how results are presented.¹⁰ So while no court will fine you for violating the Declaration of Helsinki, violating it can get your study rejected by ethics reviewers, your paper rejected by journals, and your professional reputation seriously damaged.

The relationship between the Declaration and actual law varies by country. In the United States, the primary regulatory framework for research ethics comes from the Belmont Report and the federal regulations built on it, known informally as the Common Rule. The Belmont Report does not mention the Declaration of Helsinki, and the U.S. federal government has never formally adopted the Declaration as its standard.¹¹ In Europe, the Declaration’s influence is more direct: EU clinical trial regulations reference it explicitly. The result is a patchwork where the Declaration’s moral authority is universal but its regulatory force depends on where you are.

Informed Consent and Biobanks

Informed consent has been central to the Declaration since the beginning, but the concept has grown more complicated as research has changed. The classic picture of informed consent involves a doctor sitting down with a patient, explaining a study, and getting a signature on a form. That model still applies to traditional clinical trials, but it fits awkwardly with many modern research designs.

Consider biobanks: large repositories of blood samples, tissue specimens, and genetic data collected from thousands or millions of people. A researcher in 2035 may want to use your blood sample, donated in 2020, for a study that nobody had conceived of when you gave consent. The Declaration acknowledges this tension. It requires physicians to seek informed consent for the collection, storage, and reuse of identifiable human material, but it also recognizes that there are exceptional situations where obtaining consent is impossible or impractical. In those cases, the research can proceed only after review and approval by an ethics committee.¹²

The 2024 revision expanded the Declaration’s scope to explicitly cover research on human data and human cells and tissues, not just research involving living participants.¹³ This matters because an enormous amount of modern medical research involves analyzing electronic health records, genetic databases, or stored tissue samples without ever interacting with a living person. The ethical stakes are real, especially around data privacy, but they are different from the stakes in a drug trial where someone might experience physical side effects.

Ethics During Pandemics

The COVID-19 pandemic tested every ethical framework in existence, and the Declaration of Helsinki was no exception. The pressure to develop vaccines and treatments at unprecedented speed created enormous tension between the urgency of the crisis and the deliberate, protective processes that research ethics demands. In South Korea, a review of pandemic-era research found recurring concerns about maintaining informed consent standards when the need for knowledge felt desperate and the usual bureaucratic timelines seemed like a luxury.

The 2024 revision addressed this directly with a new provision stating that “while new knowledge and interventions may be urgently needed during public health emergencies, it remains essential to uphold the ethical principles in this Declaration during such emergencies.”¹⁴ The language is a deliberate lesson from COVID-19. It acknowledges the urgency but draws a firm line: a pandemic does not reduce the importance of ethical principles. Informed consent must be retained even when time is short and the stakes are high.

This provision matters because emergencies create exactly the conditions in which ethical shortcuts are most tempting. People who are frightened and desperate may agree to participate in studies they would otherwise refuse. Governments may pressure ethics committees to approve protocols faster than usual. The Declaration’s pandemic language is intended as an anchor, a reminder that the principles exist precisely for moments when they are hardest to follow.

The Role of Ethics Committees and Institutional Review Boards

The Declaration does not replace the bodies that actually review and approve research. It explicitly states that the revised document “does not replace the roles of the Institutional Review Board and the local Ethics Committee in reviewing and approving all research study protocols but continues to provide ethical guidance for the individuals who support, review, and conduct medical research.”¹⁵ Think of the Declaration as a set of principles that ethics committees use to calibrate their decisions, not as a rulebook that answers specific questions for them.

In practice, this means that two ethics committees in different countries might read the same Declaration and reach different conclusions about the same study protocol. The document provides a shared ethical vocabulary and a common set of commitments, but it leaves significant room for interpretation. That flexibility is both a strength and a weakness. It allows the Declaration to apply across wildly different legal systems, healthcare structures, and cultural contexts. But it also means that the protections a participant receives depend substantially on the quality and independence of the local ethics committee reviewing the study.

How the Declaration Compares to Other Ethical Frameworks

The Declaration of Helsinki is not the only game in town, and understanding where it fits among other frameworks helps explain both its power and its limitations. The Nuremberg Code, adopted in 1947, was the first modern statement of research ethics, but it was narrow in scope and focused heavily on voluntary consent as an absolute requirement. The Declaration expanded on it by addressing a broader range of ethical concerns, from risk minimization to post-trial access.

In the United States, the Belmont Report (1979) serves as the foundation for federal research ethics regulations. It identifies three core principles: respect for persons, beneficence, and justice. It does not reference the Declaration, and the two documents have occasionally diverged on specific issues, particularly around the use of placebos.¹⁶ The CIOMS guidelines, developed jointly by the Council for International Organizations of Medical Sciences and the World Health Organization, offer more detailed guidance for research conducted across international borders, with particular attention to research in resource-limited settings.

Researchers who work internationally often navigate all three of these frameworks simultaneously. A clinical trial run by a U.S. university in a South American country, for example, must satisfy the Belmont Report’s requirements to receive U.S. federal funding, the host country’s ethics regulations (which may reference the Declaration), and any additional standards imposed by the journal where the researchers hope to publish. The Declaration of Helsinki’s influence is strongest at the journal and professional-association level, where its authority is nearly universal even in countries whose governments have not formally adopted it.

Pediatric Research and Online Studies

One area where the Declaration’s principles encounter practical headaches is research involving children. The standard consent model assumes a competent adult making an autonomous decision, but children cannot legally or developmentally consent to research participation. The Declaration requires that additional protections be put in place for people who cannot consent on their own, with consent obtained from a legally authorized representative and, where possible, assent from the child.

The rise of online and mobile-platform research has made this even trickier. When a study is conducted entirely through a smartphone app, how do you verify that a parent actually provided permission? How do you ensure that a 12-year-old’s assent was genuinely voluntary and not just a quick tap on an “I agree” button? These are not hypothetical problems. Researchers who want to collect health data from minors through digital platforms face a tangle of ethical, legal, and technological challenges that the Declaration’s principles frame but do not resolve in detail. The field is still working out practical solutions, and the answers often vary by jurisdiction and by the specific risks involved in the study.